Italy’s antitrust regulator fined Novartis AG (NOVN) and Roche Holding AG (ROG) 182.5 million euros ($251 million) for allegedly colluding to prevent the use of Roche’s Avastin cancer drug as a treatment for an eye disease. Roche and Novartis blocked distribution of Avastin in favor of a more expensive drug, Lucentis, that the two companies market jointly for an eye malady known as wet age-related macular degeneration, the regulator said in a website statement today. Novartis must pay 92 million euros and Roche 90.5 million euros, the agency said.
Help employers find you! Check out all the jobs and post your resume.
